肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

如何治疗间皮素阳性晚期实体瘤？新型T细胞疗法TC-210有效性显著

2020-07-27 Allan MedSci原创

实体瘤T细胞疗法TC-210
关注

T细胞疗法候选药物TC-210目前正处于I/II期临床阶段，以治疗间皮素阳性非小细胞肺癌（NSCLC）、卵巢癌、胸膜/腹膜间皮瘤和胆管癌。

TCR2是一家免疫疗法公司，正在研发一系列针对癌症患者的新型T细胞疗法，目前，该公司针对实体瘤的T细胞疗法候选药物TC-210目前正处于I/II期临床阶段，以治疗间皮素阳性非小细胞肺癌（NSCLC）、卵巢癌、胸膜/腹膜间皮瘤和胆管癌。TCR2今日宣布，在I/II期临床试验中，所有5例患者在经TC-210治疗后均显示出肿瘤消退，仅一名患者表现出与TC-210相关的非血液学毒性，无神经毒性。

TCR2总裁兼首席执行官Garry Menzel博士说：“我们很高兴看到TC-210在晚期实体瘤患者中取得的临床获益。实体瘤患者的治疗选择很少，间皮素阳性患者代表了尚未满足的医疗需求”。间皮素（Mesothelin）是一种分子量为40kDa的细胞表面糖蛋白，高表达于多种肿瘤组织中，也可表达于正常胸膜、心包和腹膜的间皮细胞中。间皮素（Mesothelin）也是胰腺癌的早期生物标志物。

 

原始出处：

https://www.firstwordpharma.com/node/1743573?tsid=4

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=806334, encodeId=44f6806334b1, content=间皮素阳性治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/41C3A62A59564EB65D498614621E966F/100, createdBy=539f1963836, createdName=武亚晶, createdTime=Wed Aug 05 15:54:31 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443148, encodeId=5dd7144314844, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Wed Jul 29 11:41:55 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478044, encodeId=f39114e8044ff, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Wed Jul 29 11:41:55 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804803, encodeId=542080480373, content=新药？, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/7bb72bd6ef034fbab8532b2870d918b9/e2001f456ec94a43adb08b38101220b8.jpg, createdBy=d7055192198, createdName=ms6487490578077260, createdTime=Mon Jul 27 22:02:51 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
    2020-08-05 武亚晶

    间皮素阳性治疗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=806334, encodeId=44f6806334b1, content=间皮素阳性治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/41C3A62A59564EB65D498614621E966F/100, createdBy=539f1963836, createdName=武亚晶, createdTime=Wed Aug 05 15:54:31 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443148, encodeId=5dd7144314844, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Wed Jul 29 11:41:55 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478044, encodeId=f39114e8044ff, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Wed Jul 29 11:41:55 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804803, encodeId=542080480373, content=新药？, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/7bb72bd6ef034fbab8532b2870d918b9/e2001f456ec94a43adb08b38101220b8.jpg, createdBy=d7055192198, createdName=ms6487490578077260, createdTime=Mon Jul 27 22:02:51 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
    2020-07-29 446798725_87912766

    #晚期实体瘤#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=806334, encodeId=44f6806334b1, content=间皮素阳性治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/41C3A62A59564EB65D498614621E966F/100, createdBy=539f1963836, createdName=武亚晶, createdTime=Wed Aug 05 15:54:31 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443148, encodeId=5dd7144314844, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Wed Jul 29 11:41:55 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478044, encodeId=f39114e8044ff, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Wed Jul 29 11:41:55 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804803, encodeId=542080480373, content=新药？, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/7bb72bd6ef034fbab8532b2870d918b9/e2001f456ec94a43adb08b38101220b8.jpg, createdBy=d7055192198, createdName=ms6487490578077260, createdTime=Mon Jul 27 22:02:51 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
    2020-07-29 124984edm24暂无昵称

    #T细胞疗法#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=806334, encodeId=44f6806334b1, content=间皮素阳性治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/41C3A62A59564EB65D498614621E966F/100, createdBy=539f1963836, createdName=武亚晶, createdTime=Wed Aug 05 15:54:31 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443148, encodeId=5dd7144314844, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Wed Jul 29 11:41:55 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478044, encodeId=f39114e8044ff, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Wed Jul 29 11:41:55 CST 2020, time=2020-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804803, encodeId=542080480373, content=新药？, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200727/7bb72bd6ef034fbab8532b2870d918b9/e2001f456ec94a43adb08b38101220b8.jpg, createdBy=d7055192198, createdName=ms6487490578077260, createdTime=Mon Jul 27 22:02:51 CST 2020, time=2020-07-27, status=1, ipAttribution=)]
    2020-07-27 ms6487490578077260

    新药？

    0

相关资讯

TLR9激动剂治疗实体瘤：已取得积极的临床前数据

LIDDS制药公司使用NanoZolid®技术制造的TLR9激动剂（NZ-TLR9）进行了临床前研究，结果表明，单次注射NZ-TLR9阻碍了肿瘤的生长并提高了存活率。

Lancet Oncol：Larotrectinib治疗TRK融合阳性晚期实体瘤

基于55例患者的初步分析，选择性TRK抑制剂larotrectinib已被批准用于晚期TRK融合基因阳性的实体肿瘤的儿科和成人患者。本研究目的是在更大规模中评估larotrectinib用于TRK融合基因阳性实体瘤患者的疗效和长期安全性。本研究招募实体瘤患者（儿童、青少年、成人），纳入标准为至少一个月大、局部晚期或转移性非中枢神经系统原发、TRK融合阳性。本次分析还包括了之前的55位患者。受试患者

Science：BioNTech针对实体瘤的新型CAR-T疗法在小鼠模型中使肿瘤完全消退

BioNTech宣布其针对实体瘤的新型CAR-T疗法的研究发表在Science杂志上，题目为"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors"，报道了BioNTech的首个CAR-T产品候选物BNT211的临床前概念验证数据，这是一种针对癌胚细胞Claudin 6（CL

实体瘤的潜力靶点：CD73势头正猛

对于实体瘤治疗而言，要克服提高的疗效，很重要的一个方面就是解除肿瘤微环境（TME）对免疫效应细胞的抑制作用。CD73是癌症中免疫抑制微环境形成的关键成分之一，并且越来越多的研究证明了其在许多实体瘤中的影响。因此，CD73成了市场上炙手可热的靶点之一。

“巨噬细胞免疫疗法”CT-0508治疗实体瘤：优于传统细胞疗法

细胞疗法在治疗实体瘤时遇到了关键挑战，包括向肿瘤部位的运输限制、免疫抑制性肿瘤微环境以及肿瘤相关抗原的异质表达，但CARISMA的临床前数据表明CAR-M疗法可以克服这些挑战。

又一“广谱”抗癌药获批：NICE批准Rozlytrek治疗NTRK基因融合的所有实体瘤

作为一种不受组织学影响的治疗方法，该药物获批用于治疗具有NTRK基因突变融合的所有实体肿瘤，无论癌症起源于体内的何处。

拓展阅读

减少自相残杀！CAR-T细胞疗法新进展，最新Nature Cancer！

研究发现实体瘤在CART攻击下，通过TNF-α/Rab27a轴增加含肿瘤抗原sEVs分泌，致CART自相残杀。构建Se9-CART细胞可克服该问题，联合抗PD-1抗体增强实体瘤治疗效果。

大咖谈 | 实体瘤柔脑膜转移的诊断和治疗

目前脑转移治疗前瞻性研究数据少，指南呼吁进一步开展随机对照试验，以弥补针对LM的循证空白。

中国原研ADC药物YL201实现晚期实体瘤治疗重大突破！

中山大学团队开展的全球多中心 1 期 / 1b 期临床试验显示，国产原研药 YL201 治疗晚期实体瘤疗效显著，安全性可控，为相关肿瘤患者提供新选择。

STTT：突破实体瘤治疗困境，曹雪涛院士团队发表论文揭示CAR-NK细胞疗法新机制

该研究揭示，通过Neo-2/15优化CAR-NK细胞的代谢功能，能够显著增强其在代谢不良的肿瘤微环境（TME）中的活性。

肿瘤治疗的“王炸组合”来袭！结直肠癌、肺癌、血液肿瘤全面突破！这些进展值得重点关注

2024 年肿瘤研究多领域突破，实体瘤免疫、靶向、细胞疗法进展多，血液肿瘤新药研发等成果丰，跨领域研究呈新趋势。

Science：儿童实体瘤的罕见遗传结构变异图谱发布！

该论文研究了罕见的遗传结构变异对儿童实体瘤发病风险的影响，发现罕见遗传结构变异是儿童实体瘤发病的重要风险因素，占遗传负荷的1.1%到5.6%。